Active 0 6 0 6 B-chronic_disease
bacterial 7 16 7 16 I-chronic_disease
, 16 17 16 17 I-chronic_disease
viral 18 23 18 23 I-chronic_disease
, 23 24 23 24 I-chronic_disease
fungal 25 31 25 31 I-chronic_disease
, 31 32 31 32 I-chronic_disease
or 33 35 33 35 I-chronic_disease
opportunistic 36 49 36 49 I-chronic_disease
infection 50 59 50 59 I-chronic_disease

Anti 0 4 60 64 B-clinical_variable
- 4 5 64 65 I-clinical_variable
nuclear 5 12 65 72 I-clinical_variable
antibody 13 21 73 81 I-clinical_variable
( 22 23 82 83 I-clinical_variable
ANA 23 26 83 86 I-clinical_variable
) 26 27 86 87 I-clinical_variable
titer 28 33 88 93 I-clinical_variable
of 34 36 94 96 O
1:80 37 41 97 101 B-lower_bound
, 41 42 101 102 O
or 43 45 103 105 O
greater 46 53 106 113 O
, 53 54 113 114 O
as 55 57 115 117 O
determined 58 68 118 128 O
by 69 71 129 131 O
immunofluorescence 72 90 132 150 O
assay 91 96 151 156 O
( 97 98 157 158 O
IFA 98 101 158 161 O
) 101 102 161 162 O

Between 0 7 163 170 O
15 8 10 171 173 B-lower_bound
and 11 14 174 177 O
49 15 17 178 180 B-upper_bound
years 18 23 181 186 I-upper_bound
of 24 26 187 189 O
age 27 30 190 193 B-age

Co 0 2 194 196 O
- 2 3 196 197 O
morbidities 3 14 197 208 O
requiring 15 24 209 218 O
systemic 25 33 219 227 B-treatment
corticosteroid 34 48 228 242 I-treatment
therapy 49 56 243 250 I-treatment
greater 57 64 251 258 O
than 65 69 259 263 O
10 70 72 264 266 B-lower_bound
mg 73 75 267 269 I-lower_bound
of 76 78 270 272 O
prednisone 79 89 273 283 B-treatment
per 90 93 284 287 O
day 94 97 288 291 O
, 97 98 291 292 O
or 99 101 293 295 O
equivalent 102 112 296 306 O
, 112 113 306 307 O
or 114 116 308 310 O
a 117 118 311 312 O
change 119 125 313 319 O
in 126 128 320 322 O
corticosteroid 129 143 323 337 O
dose 144 148 338 342 O
within 149 155 343 349 O
the 156 159 350 353 O
3 160 161 354 355 B-upper_bound
months 162 168 356 362 I-upper_bound
prior 169 174 363 368 I-upper_bound
to 175 177 369 371 O
Visit 178 183 372 377 O
1 184 185 378 379 O

Evidence 0 8 380 388 O
of 9 11 389 391 O
infection 12 21 392 401 O
with 22 26 402 406 O
human 27 32 407 412 B-chronic_disease
immunodeficiency 33 49 413 429 I-chronic_disease
virus 50 55 430 435 I-chronic_disease
( 56 57 436 437 I-chronic_disease
HIV 57 60 437 440 I-chronic_disease
) 60 61 440 441 I-chronic_disease
, 61 62 441 442 O
Hepatitis 63 72 443 452 B-chronic_disease
B 73 74 453 454 I-chronic_disease
, 74 75 454 455 O
or 76 78 456 458 O
Hepatitis 79 88 459 468 B-chronic_disease
C 89 90 469 470 I-chronic_disease

History 0 7 471 478 O
of 8 10 479 481 O
primary 11 18 482 489 B-chronic_disease
immunodeficiency 19 35 490 506 I-chronic_disease

Participants 0 12 507 519 O
must 13 17 520 524 O
have 18 22 525 529 O
at 23 25 530 532 O
least 26 31 533 538 O
one 32 35 539 542 B-lower_bound
( 36 37 543 544 O
but 37 40 544 547 O
not 41 44 548 551 O
three 45 50 552 557 O
or 51 53 558 560 O
more 54 58 561 565 O
) 58 59 565 566 O
additional 60 70 567 577 O
clinical 71 79 578 586 O
or 80 82 587 589 O
laboratory 83 93 590 600 O
criterion 94 103 601 610 O
from 104 108 611 615 O
the 109 112 616 619 O
2012 113 117 620 624 O
Systemic 118 126 625 633 O
Lupus 127 132 634 639 O
International 133 146 640 653 O
Collaborating 147 160 654 667 O
Clinics 161 168 668 675 O
( 169 170 676 677 O
SLICC 170 175 677 682 O
) 175 176 682 683 O
classification 177 191 684 698 O
criteria 192 200 699 707 O

Pregnant 0 8 708 716 B-pregnancy
, 8 9 716 717 O
breastfeeding 10 23 718 731 O
, 23 24 731 732 O
or 25 27 733 735 O
unwilling 28 37 736 745 B-contraception_consent
to 38 40 746 748 I-contraception_consent
practice 41 49 749 757 I-contraception_consent
birth 50 55 758 763 I-contraception_consent
control 56 63 764 771 I-contraception_consent
during 64 70 772 778 O
participation 71 84 779 792 O
in 85 87 793 795 O
the 88 91 796 799 O
study 92 97 800 805 O

Starting 0 8 806 814 O
, 8 9 814 815 O
stopping 10 18 816 824 O
, 18 19 824 825 O
or 20 22 826 828 O
changing 23 31 829 837 O
the 32 35 838 841 O
dose 36 40 842 846 O
of 41 43 847 849 O
over 44 48 850 854 O
the 49 52 855 858 O
counter 53 60 859 866 O
or 61 63 867 869 O
prescription 64 76 870 882 O
non 77 80 883 886 B-treatment
- 80 81 886 887 I-treatment
steroidal 81 90 887 896 I-treatment
anti 91 95 897 901 I-treatment
- 95 96 901 902 I-treatment
inflammatory 96 108 902 914 I-treatment
drugs 109 114 915 920 I-treatment
( 115 116 921 922 I-treatment
NSAIDs 116 122 922 928 I-treatment
) 122 123 928 929 I-treatment
in 124 126 930 932 O
the 127 130 933 936 O
three 131 136 937 942 B-upper_bound
months 137 143 943 949 I-upper_bound
prior 144 149 950 955 I-upper_bound
to 150 152 956 958 O
Visit 153 158 959 964 O
1 159 160 965 966 O

The 0 3 967 970 O
subject 4 11 971 978 O
has 12 15 979 982 O
been 16 20 983 987 O
diagnosed 21 30 988 997 O
with 31 35 998 1002 O
another 36 43 1003 1010 O
autoimmune 44 54 1011 1021 B-chronic_disease
disorder 55 63 1022 1030 I-chronic_disease
, 63 64 1030 1031 O
other 65 70 1032 1037 O
than 71 75 1038 1042 O
autoimmune 76 86 1043 1053 B-chronic_disease
thyroid 87 94 1054 1061 I-chronic_disease
conditions 95 105 1062 1072 I-chronic_disease

The 0 3 1073 1076 O
subject 4 11 1077 1084 O
has 12 15 1085 1088 O
other 16 21 1089 1094 O
contraindications 22 39 1095 1112 O
to 40 42 1113 1115 O
treatment 43 52 1116 1125 B-treatment
with 53 57 1126 1130 I-treatment
hydroxychloroquine 58 76 1131 1149 I-treatment
including 77 86 1150 1159 O
pre 87 90 1160 1163 O
- 90 91 1163 1164 O
existing 91 99 1164 1172 O
ocular 100 106 1173 1179 B-chronic_disease
disease 107 114 1180 1187 I-chronic_disease
, 114 115 1187 1188 O
hepatic 116 123 1189 1196 B-chronic_disease
impairment 124 134 1197 1207 I-chronic_disease
, 134 135 1207 1208 O
psoriasis 136 145 1209 1218 B-chronic_disease
, 145 146 1218 1219 O
porphyria 147 156 1220 1229 B-chronic_disease
, 156 157 1229 1230 O
or 158 160 1231 1233 O
allergy 161 168 1234 1241 O
to 169 171 1242 1244 O
the 172 175 1245 1248 O
drug 176 180 1249 1253 B-allergy_name
or 181 183 1254 1256 I-allergy_name
class 184 189 1257 1262 I-allergy_name

The 0 3 1263 1266 O
subject 4 11 1267 1274 O
has 12 15 1275 1278 O
previously 16 26 1279 1289 O
been 27 31 1290 1294 O
or 32 34 1295 1297 O
is 35 37 1298 1300 O
currently 38 47 1301 1310 O
being 48 53 1311 1316 O
treated 54 61 1317 1324 O
with 62 66 1325 1329 O
oral 67 71 1330 1334 B-treatment
antimalarial 72 84 1335 1347 I-treatment
agents 85 91 1348 1354 I-treatment
including 92 101 1355 1364 O
hydroxychloroquine 102 120 1365 1383 B-treatment
, 120 121 1383 1384 O
chloroquine 122 133 1385 1396 O
, 133 134 1396 1397 O
or 135 137 1398 1400 O
quinacrine 138 148 1401 1411 B-treatment

The 0 3 1412 1415 O
subject 4 11 1416 1423 O
has 12 15 1424 1427 O
significant 16 27 1428 1439 O
findings 28 36 1440 1448 O
on 37 39 1449 1451 O
ophthalmological 40 56 1452 1468 B-treatment
examination 57 68 1469 1480 I-treatment
that 69 73 1481 1485 O
, 73 74 1485 1486 O
in 75 77 1487 1489 O
the 78 81 1490 1493 O
opinion 82 89 1494 1501 O
of 90 92 1502 1504 O
the 93 96 1505 1508 O
examining 97 106 1509 1518 O
Ophthalmologist 107 122 1519 1534 O
, 122 123 1534 1535 O
prevent 124 131 1536 1543 O
safe 132 136 1544 1548 O
use 137 140 1549 1552 O
of 141 143 1553 1555 O
hydroxychloroquine 144 162 1556 1574 B-treatment

The 0 3 1575 1578 O
subject 4 11 1579 1586 O
is 12 14 1587 1589 O
currently 15 24 1590 1599 O
or 25 27 1600 1602 O
has 28 31 1603 1606 O
been 32 36 1607 1611 O
treated 37 44 1612 1619 O
with 45 49 1620 1624 O
immunosuppressive 50 67 1625 1642 B-treatment
, 67 68 1642 1643 O
immune 69 75 1644 1650 B-treatment
modifying 76 85 1651 1660 I-treatment
, 85 86 1660 1661 O
or 87 89 1662 1664 O
cytotoxic 90 99 1665 1674 B-treatment
medications 100 111 1675 1686 I-treatment
as 112 114 1687 1689 O
listed 115 121 1690 1696 O
in 122 124 1697 1699 O
Section 125 132 1700 1707 O
7.2 133 136 1708 1711 O

